financetom
Business
financetom
/
Business
/
Marchex Q3 revenue misses estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Marchex Q3 revenue misses estimates
Nov 13, 2025 1:55 PM

Overview

* Marchex ( MCHX ) Q3 revenue declines to $11.5 mln, missing analyst expectations

* Adjusted EBITDA for Q3 2025 misses estimates despite improvement

* Company announces agreement to acquire Archenia, enhancing AI capabilities

Outlook

* Marchex expects Q4 2025 revenue and Adjusted EBITDA to be sequentially lower

* Company anticipates 10% revenue growth in 2026 on a run rate basis

* Marchex ( MCHX ) expects Adjusted EBITDA margins of 10% or more in 2026

Result Drivers

* REVENUE MIGRATION DILUTION - Co cites ongoing revenue migration dilution as a factor in revenue decline during tech platform migration

* SALES BOOKINGS INCREASE - Co reports significant increases in sales bookings, expecting continued growth

* NEW PRODUCT LAUNCHES - Co launched new products and vertical AI capabilities, contributing to sales growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $11.51 $11.90

Revenue mln mln (1

Analyst)

Q3 Net -$1.02

Income mln

Q3 Miss $621,000 $826,000

Adjusted (1

EBITDA Analyst)

Q3 -$941,00

Income 0

from

Operatio

ns

Q3 $12.46

Operatin mln

g

Expenses

Analyst Coverage

* The one available analyst rating on the shares is "buy"

* The average consensus recommendation for the advertising & marketing peer group is "buy"

* Wall Street's median 12-month price target for Marchex Inc ( MCHX ) is $4.00, about 60% above its November 12 closing price of $1.60

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
Jan 7, 2025
(This Dec. 27 story has been corrected to say Opdivo Qvantig has been approved to treat most previously approved tumor indications, not all previously approved tumor indications, in paragraph 5) By Sneha S K and Sriparna Roy (Reuters) - The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster...
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo (Dec. 27)
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo (Dec. 27)
Jan 7, 2025
By Sneha S K and Sriparna Roy Dec 27 (Reuters) - The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ( BMY ) blockbuster cancer drug, Opdivo. Opdivo is part of a class of drugs called PD-1 inhibitors, which enhance the immune system's ability to fight cancer by removing...
Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst
Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst
Jan 7, 2025
Barclays analyst Matt Miksic initiated coverage on Anteris Technologies Global Corp. ( AVR ) with a Positive rating and a forecast of $22. The analyst notes that Anteris Technologies’ DurAVR valve system is expected to become the second balloon-expandable transcatheter valve replacement (BEV TAVR) system by 2028 Clinicians show a clear preference for BEV TAVR systems over self-expanding (SEV) systems...
Cushman & Wakefield, Camden, Blackstone's LivCor Sued by DOJ Over Alleged Rent Pricing Scheme
Cushman & Wakefield, Camden, Blackstone's LivCor Sued by DOJ Over Alleged Rent Pricing Scheme
Jan 7, 2025
02:39 PM EST, 01/07/2025 (MT Newswires) -- Cushman & Wakefield ( CWK ) , Camden Property Trust ( CPT ) , and Blackstone's (BX) LivCor are among the landlords facing a lawsuit filed by the US Department of Justice Tuesday for allegedly participating in an algorithmic pricing scheme. The three landlords along with Greystar Real Estate Partners, Cushman & Wakefield's...
Copyright 2023-2026 - www.financetom.com All Rights Reserved